Inactive Instrument

Cesca Therapeutics Inc Stock Nasdaq

Equities

US1571311034

Office Equipment

Sales 2022 10.48M 14.36M Sales 2023 9.44M 12.94M Capitalization 1.89M 2.58M
Net income 2022 -11M -15.07M Net income 2023 -18M -24.67M EV / Sales 2022 0.97 x
Net Debt 2022 6.89M 9.44M Net Debt 2023 9.28M 12.72M EV / Sales 2023 1.18 x
P/E ratio 2022
-0.16 x
P/E ratio 2023
-0.08 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 44.17%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 53 16-03-09
Director of Finance/CFO 51 09-12-31
Investor Relations Contact - -
Members of the board TitleAgeSince
Chief Executive Officer 53 16-03-09
Director/Board Member - 23-07-13
More insiders
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
More about the company